Pathophysiology, Detection and Prevention of Neurological Adverse Events in Cancer Patients

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 1901

Special Issue Editors


E-Mail Website
Guest Editor
Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany
Interests: chemotherapy-induced neuropathy; immune related adverse events; neuroprotection; neurotoxicology; neurodegeneration

E-Mail Website
Guest Editor
Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany
Interests: post-chemotherapy cognitive impairment; immune effector cell-associated neurotoxicity syndrome; biomarkers; neurotoxicology; neuroprotection

Special Issue Information

Dear Colleagues,

Treatments for malignant diseases have become increasingly diverse over the past decade, as have the neurological side effects of tumor therapies. The neurological adverse events of complex treatment strategies, including cytotoxic substances, radiotherapy, immunotherapy, cell-based therapies, and targeted molecular therapies in mono and combination therapy, are creating an increasingly complex interdisciplinary challenge. As all sections of the nervous system can be damaged, the clinical spectrum is very broad and, still for many conditions, incompletely understood. With this Special Issue, we would like to follow a patient-centered approach in focusing on mechanistic insights and cell biology leading to neurological adverse events, and we invite the submission of preclinical and translational articles that improve our knowledge about underlying pathophysiological processes and biomarkers as well as novel neuroprotective approaches.

Dr. Wolfgang Boehmerle
Dr. Petra Huehnchen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chemotherapy-induced neuropathy
  • post-chemotherapy cognitive impairment
  • immune related adverse events
  • immune effector cell-associated neurotoxicity syndrome
  • radiotoxicity

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 9490 KiB  
Article
Glycyrrhizic Acid Prevents Paclitaxel-Induced Neuropathy via Inhibition of OATP-Mediated Neuronal Uptake
by Ines Klein, Jörg Isensee, Martin H. J. Wiesen, Thomas Imhof, Meike K. Wassermann, Carsten Müller, Tim Hucho, Manuel Koch and Helmar C. Lehmann
Cells 2023, 12(9), 1249; https://doi.org/10.3390/cells12091249 - 25 Apr 2023
Cited by 3 | Viewed by 1658
Abstract
Peripheral neuropathy is a common side effect of cancer treatment with paclitaxel. The mechanisms by which paclitaxel is transported into neurons, which are essential for preventing neuropathy, are not well understood. We studied the uptake mechanisms of paclitaxel into neurons using inhibitors for [...] Read more.
Peripheral neuropathy is a common side effect of cancer treatment with paclitaxel. The mechanisms by which paclitaxel is transported into neurons, which are essential for preventing neuropathy, are not well understood. We studied the uptake mechanisms of paclitaxel into neurons using inhibitors for endocytosis, autophagy, organic anion-transporting polypeptide (OATP) drug transporters, and derivatives of paclitaxel. RT-qPCR was used to investigate the expression levels of OATPs in different neuronal tissues and cell lines. OATP transporters were pharmacologically inhibited or modulated by overexpression and CRISPR/Cas9-knock-out to investigate paclitaxel transport in neurons. Through these experiments, we identified OATP1A1 and OATP1B2 as the primary neuronal transporters for paclitaxel. In vitro inhibition of OATP1A1 and OAT1B2 by glycyrrhizic acid attenuated neurotoxicity, while paclitaxel’s antineoplastic effects were sustained in cancer cell lines. In vivo, glycyrrhizic acid prevented paclitaxel-induced toxicity and improved behavioral and electrophysiological measures. This study indicates that a set of OATPs are involved in paclitaxel transport into neurons. The inhibition of OATP1A1 and OATP1B2 holds a promising strategy to prevent paclitaxel-induced peripheral neuropathy. Full article
Show Figures

Figure 1

Back to TopTop